Amylyx stock soars on GLP-1 success: here's why investors should sell

Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluate...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。